1. Introduction {#s0005}
===============

The preclinical phase of Alzheimer\'s disease (AD), which is thought to begin a decade or more prior to a clinical diagnosis of dementia due to AD, is characterized by neuropathological changes but intact cognitive and functional abilities ([@bb0235]; [@bb0230]). Several biomarkers exist for detecting AD-related neuropathology in vivo across the AD continuum. Recently, Jack and colleagues proposed a framework for defining abnormal pathophysiology in AD by dividing these biomarkers into three distinct categories ([@bb0150], [@bb0160]) of amyloid burden (A) (e.g., decreased cerebrospinal fluid (CSF) levels of Aβ~42~ or elevated retention of amyloid PET tracers), tau tangle pathology (T) (e.g., elevations in tau tracer retention on PET or increased CSF levels of phosphorylated tau (ptau~181~)), and neurodegeneration (N) (e.g., \[^18^F\]-fluorodeoxyglucose (FDG)-PET hypometabolism, elevated CSF levels of total tau, or gray matter loss measured using structural MRI). Within the context of this AT(N) framework, individuals can be categorized as A, T, and/or N positive or negative, resulting in eight possible groups.

In order to classify individuals across the AD continuum (i.e., individuals who are A+) using A, T, and N, one must first develop cut-off values for each of these three categories of biomarkers, and such thresholds may be site-specific. Numerous studies demonstrate sensitive and specific cut-off values for both A and T in individuals in the earliest stages of AD (e.g., [@bb0055]; [@bb0130]; [@bb0185]; [@bb0265]), and the field is improving precision in this regard with new CSF platforms for analysis ([@bb0030]; [@bb0305]). There is relatively greater heterogeneity in defining N across the AD continuum, particularly with MRI. MRI morphometric approaches for assessing atrophy are abundant, but may vary at several levels including acquisition (field strength and sequence parameters), neuroanatomic operationalization of structures of interest, choice of software, reliability and precision of the measure of interest, computational availability, and end-user expertise and decision rules to evaluate the output. Furthermore, unlike A and T, N is not necessarily specific to AD pathophysiology. For example, a marked increase in CSF total tau (as a surrogate indicator of N) is seen both with acute brain damage, such as ischemic stroke ([@bb0135]), as well as in rapidly progressive neurodegenerative disorders such as Creutzfeldt-Jakob disease ([@bb0270]). Nevertheless, prior investigations report that A + T + N+ individuals are more likely to evidence cognitive decline than not only A-T-N- individuals, but also their A + T + N- counterparts ([@bb0015]; [@bb0035]; [@bb0065]; [@bb0155]; [@bb0280]; [@bb0295]; [@bb0300]; [@bb0310]). These findings suggest that N, in conjunction with A and T, may provide important staging information for AD ([@bb0160]).

A number of N metrics are currently available for AD-related staging. One of the most readily available methods comes from morphometric estimates obtained using structural MRI. Structural MRI studies examining N in AD have frequently focused on hippocampal volume ([@bb0140]; [@bb0285]; [@bb0295]), global atrophy ([@bb0090]; [@bb0115]; [@bb0255]; [@bb0295]), and an "AD signature" consisting of a composite of thickness or volumetric estimates derived from regions impacted early during the course of AD ([@bb0080]; [@bb0075]; [@bb0260]). A previous study, which compared multiple thickness- and volumetric-based methods for obtaining an AD signature, found that thickness-based AD signatures from FreeSurfer and Statistical Parametric Mapping (SPM) + DiReCT (the cortical thickness algorithm from Advanced Normalization Tools (ANTs)) had the strongest correlations with Braak neurofibrillary tangle stage at autopsy ([@bb0260]). It should be noted that SPM + DiReCT was found to have better test-retest reliability than FreeSurfer, although FreeSurfer performed better in terms of diagnostic separability. As a result, Schwarz et al. recommended either method as appropriate for obtaining an AD signature estimate.

Compared to completely automated methods, FreeSurfer can require iterative manual editing of segmentation output and this practice may vary between laboratories. Further, the automated segmentation component itself can be time consuming, with a recent study suggesting that FreeSurfer 6.0 takes approximately 6--9 h per scan to complete this component ([@bb0085]), with the total amount of time depending upon a number of parameters (e.g., processor speed and workflow type) and control point editing iterations. Given these drawbacks, it may be that less user- and computationally-intensive estimates obtained from structural MRI with quicker quality control procedures, such as hippocampal volume and global atrophy estimates derived from FMRIB Software Library (FSL)-FIRST (a tool designed to segment subcortical structures) and SPM respectively, are sufficient in many settings for defining N in the context of AD.

One way to determine whether hippocampal volume and global atrophy are equivalent to the thickness-based AD signature from FreeSurfer is to follow a similar approach as outlined in [@bb0260] by comparing the diagnostic accuracy of these three estimates for separating individuals with AD dementia from cognitively unimpaired (CU) individuals. Alternatively, we could compare the three MRI-based morphometric estimates to a reference standard. Unfortunately, no "gold standard" for defining N currently exists; however, CSF levels of neurofilament light chain protein (NfL) may be a relatively good reference standard in light of prior investigations.

Several previous studies have demonstrated that CSF NfL is a biomarker of axonal injury in multiple neurodegenerative conditions, including AD ([@bb0215]; [@bb0225]; [@bb0330]; [@bb0335]). Furthermore, CSF NfL has been found to be associated with accelerated disease progression and atrophy rates (both hippocampal and whole brain), as well as differentiates individuals with AD from CU individuals and those with mild cognitive impairment (MCI) ([@bb0335]). A prior meta-analysis noted that CSF NfL had a large effect size for differentiating CU individuals from those with AD, whereas CSF levels of other N markers (e.g., visinin-like protein 1 and neuron-specific enolase) only demonstrated moderate effect sizes ([@bb0215]). Finally, recent research has found elevated CSF levels of NfL in both symptomatic and asymptomatic carriers of the presenilin-1 or amyloid precursor protein mutation, as well as noted associations between CSF NfL and both cognitive and imaging measures (e.g., global atrophy rate) in this group with familial AD ([@bb0325]). Together, these findings suggest that CSF NfL is a useful metric for defining N across the AD continuum, including during the earliest phase of the disease.

In light of the findings reviewed above, the primary goal of the current study was to compare the more computationally expensive and user intensive AD signature to automated, robust, and computationally efficient estimates of hippocampal volume and global atrophy for the purpose of defining N in individuals across the AD continuum (i.e., individuals who are A+). To accomplish this goal, we: 1) examined the diagnostic accuracy of each measure for separating A+ AD individuals from A-T- CU individuals; 2) identified cut-off values for several measures of N; 3) evaluated the association between N defined using CSF NfL and the three MRI-based measures; and 4) examined the ability of these N measures to differentiate A-T- CU individuals from those along the AD continuum (i.e., from A+T- CU to A+ AD individuals).

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

Participants consisted of late middle-aged and older adults (*n* = 325, mean age = 62; 309 individuals reported their race as White, 1 as Hispanic, 6 as Black or African American, 2 as Asian, and 7 as Native American or Alaskan Native; see [Table 1](#t0005){ref-type="table"} for sample characteristics) enrolled in longitudinal cohort studies at the Wisconsin Alzheimer\'s Disease Research Center (WADRC) or the Wisconsin Registry for Alzheimer\'s Prevention (WRAP; [@bb0165]). To qualify for the current analysis, participants were required to have at least one T1-weighted structural MRI scan (to define N) and one lumbar puncture (with available CSF data for Aβ~42~, ptau~181~, total tau, and NfL) within 1.5 years of each other (mean time between lumbar puncture and MRI scan = 0.03 years, standard deviation = 0.14 years, range = 0--1.17 years). Participants were also required to be classified as CU (i.e., no clinical diagnosis of MCI or dementia), MCI due to AD, or dementia due to AD. These classifications were made by a team of clinicians (neuropsychologists, physician dementia specialists, and nurse practitioners) blind to biomarker status, and were based on consensus conference research criteria established by the National Institute on Aging-Alzheimer\'s Association ([@bb0005]; [@bb0190]). Participants were then categorized as biomarker negative (i.e., A-T-) or biomarker positive (A+) based on available CSF data (for more details about cut-off values for A and T, see the section on amyloid and tau status determination below). Participants in the MCI or dementia due to AD groups were required to be A+ and participants in the CU group were required to be either A-T-, A+T-, or A + T+ so as to represent individuals across the AD continuum ([@bb0160]). All participants were free from major psychiatric conditions (e.g., schizophrenia or bipolar disorder) and excluded from the current analysis if they failed processing or had an abnormal MRI as described below (see [Supplemental Fig. 1](#ec0005){ref-type="supplementary-material"} for a flow diagram detailing eligibility for the current study).

The inclusion of human participants was approved by the University of Wisconsin-Madison Institutional Review Board, and all participants provided informed consent. The current work was carried out in accordance with *The Code of Ethics of the World Medical Association*.Table 1Demographics and biomarkers.Table 1Total sampleROC sampleConcordance sampleCU A-T-AD A+CU A-T-CU A+T-CU A + T+MCI A+N3252020229241616Sex (male; %)\^109 (33.5%)10 (50.0%)10 (50.0%)71 (31.0%)4 (16.7%)4 (25.0%)10 (62.5%)Age (years) (mean (SD))\*61.9 (8.0)66.7 (5.6)66.6 (5.6)59.7 (7.2)63.1 (7.5)68.5 (6.9)73.0 (8.6)Education (years) (mean (SD))+16.0 (2.5)15.2 (2.8)15.3 (2.8)16.1 (2.4)16.0 (2.8)15.8 (2.4)16.1 (2.8)LN of CSF levels of Aβ~42~ (pg/mL) (mean (SD))6.4 (0.3)6.7 (0.2)5.8 (0.2)6.6 (0.2)6.0 (0.2)6.0 (0.1)5.9 (0.2)CSF levels of ptau~181~ (pg/mL) (mean (SD))43.6 (17.9)39.5 (8.6)70.0 (21.2)38.6 (10.0)38.5 (13.3)69.5 (16.5)69.8 (37.0)CSF levels of tau (pg/mL) (mean (SD))339.1 (204.1)293.0 (62.9)714.3 (262.4)268.3 (84.3)282.3 (112.5)636.0 (178.1)728.4 (347.7)CSF levels of NfL (pg/mL) (mean (SD))731.9 (457.0)692.9 (160.7)1281.1 (717.9)622.1 (286.5)701.4 (373.8)1025.7 (304.2)1417.2 (1043.3)AD Signature (z-score) (mean (SD))0.0 (1.0)0.2 (0.7)−1.6 (1.0)0.2 (0.9)−0.1 (0.7)−0.2 (0.8)−1.3 (1.0)Hippocampal Volume (z-score) (mean (SD))0.0 (1.0)−0.2 (0.5)−1.4 (0.9)0.3 (0.9)−0.2 (0.7)−0.1 (0.8)−1.4 (0.7)Global Atrophy (z-score) (mean (SD))0.0 (1.0)0.2 (0.8)1.8 (0.8)−0.3 (0.7)0.1 (0.9)0.3 (1.0)1.5 (1.0)[^1]

### 2.1.1. ROC participants {#s0020}

A+ individuals with a clinical diagnosis of probable AD dementia were matched to biomarker-negative CU individuals (i.e., A-T- individuals based on available CSF) on the following demographic variables: age, sex, and education. Six individuals with dementia due to AD were excluded from the analysis because there was not an age-, sex-, and education-matched biomarker-negative CU individual available. This resulted in 20 A+ individuals with a clinical diagnosis of probable AD and 20 A-T- CU individuals for the ROC analyses. Of the 20 A+ individuals with a clinical diagnosis of probable AD, 18 were A + T+ and 2 were A+T-. The Clinical Dementia Rating Scale (CDR; [@bb0200]) was administered to informants of these 20 participants to determine the severity of dementia (9 were classified as CDR = 0.5 (i.e., very mild dementia) and 11 were classified as CDR = 1.0 (i.e., mild dementia)). For more information on the demographic characteristics of these individuals, please refer to [Table 1](#t0005){ref-type="table"} (ROC sample).

### 2.1.2. Participants used for NfL N concordance analysis {#s0025}

A-T- CU individuals who were not included in the ROC analyses, along with CU and MCI individuals who were A+, were included in analyses examining the relationship between N positivity by NfL and the MRI-based measures of N. This resulted in the inclusion of 285 individuals with known biomarker status in these analyses. For information on the demographic characteristics of these individuals, please refer to [Table 1](#t0005){ref-type="table"} (Concordance Sample).

2.2. Structural MRI {#s0030}
-------------------

Two identical GE 3.0 Tesla MR750 scanners (Waukesha, WI, USA) with an 8-channel head coil (Excite HD Brain Coil; GE Healthcare) were used to acquire a T1-weighted brain volume in the axial plane, with a 3-D inversion-recovery prepared fast spoiled gradient-echo sequence using the following parameters: inversion time (TI) = 450 ms, repetition time (TR) = 8.1 ms, echo time (TE) = 3.2 ms, flip angle = 12°, acquisition matrix = 256 × 256 × 156 mm, field of view (FOV) = 256 mm, slice thickness = 1.0 mm. Additionally, seven subjects were scanned with a shorter sequence that was less susceptible to motion artifacts, after it was determined their first scan would likely be unusable. The shorter sequence parameters were: TI = 450 ms, TR = 6.044 ms, TE = 2.204 ms, flip angle = 12°, acquisition matrix = 256 × 256 × 130 mm, FOV = 256 mm, slice thickness = 1.2 mm, in-plane resolution 1 mm. Cushions inside the head coil were used to reduce head movement during scanning. All scans were reviewed by a radiologist (H.A.R.) and 14 CU individuals were excluded for abnormalities (e.g., hydrocephalus, prior craniotomy, CHS rating \>4; [@bb0180]).

FreeSurfer 6.0 ([@bb0095]) was used for the purpose of defining an "AD signature," which consisted of a composite of thickness estimates derived from the following regions of interest (ROIs) based on previous research: entorhinal, inferior temporal, middle temporal, inferior parietal, fusiform, and precuneus ([@bb0260]). Within FreeSurfer, each gray matter voxel in an MRI image is mapped to a cortical surface mesh and given a neuroanatomical label based on a probabilistic atlas from a manually labeled training set consisting of both healthy younger and older adults as described in the software documentation ([@bb0100]). We followed a quality control process similar to that outlined by [@bb0260] in which FreeSurfer segmentation outputs were visually inspected by S.L.A. and R.P.C. for severe errors, which included when FreeSurfer failed to complete topology correction (two participants with dementia due to AD) or a significant portion of the cortical ribbon was placed incorrectly (two MCI and two CU individuals). No manual correction of FreeSurfer was performed and these six participants were excluded from analyses.

Volumetric estimates were derived from the T1-weighted IRSPGR sequence. Tissue segmentation into CSF, gray matter, white matter, and intracranial volume (ICV) was performed using SPM12 ([www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm){#ir0005}), which is an automated and completely reproducible process ([@bb0020]). Brain (the sum of total gray matter and white matter) and CSF segmentation was the objective of this process and no failures (defined as gross tissue misclassification based on visual inspection of the images by S.L.A) occurred. Hippocampal volume was estimated using the completely automated FSL-FIRST algorithm ([@bb0220]). Visual inspection of the hippocampal segmentations by S.L.A. revealed that the output misclassified the hippocampus in one dementia due to AD case that had significant structural atrophy, and this participant was excluded from analyses. For quantitative analyses, hippocampal volume was corrected for head size by proportional scaling to total intracranial volume (brain plus CSF volume derived from the SPM12 segmentation output). A simple measure of global atrophy was estimated as the ratio of CSF volume to brain volume (total gray matter volume + total white matter volume). In order to compare the three metrics, they were scaled to have a mean of 0 and a standard deviation of 1.

2.3. Cerebrospinal fluid collection {#s0035}
-----------------------------------

Twenty-two mL of CSF were removed from the L3-L4 or L4-L5 vertebral interspace. These samples (sent in batches at two time points) were analyzed at the Clinical Neurochemistry Laboratory at the Sahlgrenska Academy of the University of Gothenburg, Sweden using commercially available enzyme-linked immunosorbent assay methods. CSF samples were assayed for Aβ~42~, ptau~181~, total tau, and NfL, and corrected for batch when appropriate as described in [@bb0055].

2.4. Amyloid and tau status determination {#s0040}
-----------------------------------------

For the current study, the natural log of CSF Aβ~42~ \< 6.156 was defined as A+, whereas CSF levels of total tau \>461.26 or ptau~181~ \> 59.50 were defined as T+. We defined T+ based on either CSF levels of total tau or ptau~181~ given the high correlation between these two CSF measures in the current study (Spearman rank correlation = 0.916, *p* \< .001). These cut-off values are based on prior ROC analyses for discriminating CU individuals from those with a clinical diagnosis of MCI or dementia due to AD ([@bb0055]).

2.5. Statistical analyses {#s0045}
-------------------------

Analyses were conducted in SPSS 23. First, ROC analyses were performed to determine the sensitivity and specificity of hippocampal volume, the AD signature, global atrophy, and CSF NfL for separating A+ individuals with a clinical diagnosis of AD from A-T- CU individuals. The area under the curve (AUC), which may be defined as the accuracy of the diagnostic test (values range from 0 to 1), was computed for each metric. For each of these metrics, the value that maximized Youden\'s Index (sensitivity + specificity - 1) was chosen as the threshold for N positivity. In the event that different cut-off values evidenced identical Youden\'s Indices, the cut-off value with the highest sensitivity was selected. Cohen\'s Kappa was then used to examine the relationship between N positivity defined by NfL and each of the three MRI-based measures of N. Cohen\'s Kappa was also used to examine the relationships among the three MRI-based measures of N. We reported positive percent agreement, negative percent agreement, and overall percent agreement for each MRI-based measure in relation to NfL and in relation to each other. Separate correlation matrices of all relevant continuous measures of A, T, and N were also computed for the whole sample (*n* = 325) and for the concordance sample (*n* = 285) using age-adjusted partial correlations and Spearman rank correlations.

Finally, we wanted to examine the measures of N in the context of staging across the AD continuum. Therefore, we performed Kruskal-Wallis tests ([@bb0040]) to determine if there was a significant relationship between group membership (i.e., A-T- CU, A+T- CU, A + T+ CU, A+ MCI, and A+ AD individuals) and each measure of N (i.e., CSF NfL, AD signature, hippocampal volume, and global atrophy). Post-hoc analyses comparing the A-T- CU group to each of the four remaining groups were accomplished using Mann-Whitney *U* tests ([@bb0175]). Cliff\'s delta was used to compute the effect size of each of the three MRI-based measures of N and NfL ([@bb0060]).

Post-hoc analyses adjusting for age were also performed in the context of staging across the entire AD continuum for Kruskal-Wallis tests, Cliff\'s deltas, and Mann-Whitney *U* tests. First, using only the A-T- CU group, separate regressions were performed with each measure of N as an outcome in separate analyses and age as the predictor. The intercept β, age β, and the square root of the mean square error (RMSE) were saved. These parameters were then used for the whole sample (n = 325) to get the predicted N value based on the A-T- CU group age-related change. An individual\'s unadjusted z-score on each N metric was converted to an age-adjusted z-score as follows:

age-adjusted z-score for the N metric = (observed z-score - predicted z-score)/RMSE.

3. Results {#s0050}
==========

3.1. Demographics {#s0055}
-----------------

Participants were on average 62 years old, 34% male, and highly educated (see [Table 1](#t0005){ref-type="table"}).

3.2. Determining cut-off values for each neurodegeneration measure[1](#fn0005){ref-type="fn"} {#s0060}
---------------------------------------------------------------------------------------------

CSF NfL ([Fig. 1](#f0005){ref-type="fig"}A), the AD signature ([Fig. 1](#f0005){ref-type="fig"}B), hippocampal volume ([Fig. 1](#f0005){ref-type="fig"}C), and global atrophy ([Fig. 1](#f0005){ref-type="fig"}D) all significantly discriminated between the A-T- CU (*n* = 20) and A+ AD dementia (n = 20) groups (see [Table 2](#t0010){ref-type="table"} for each metric\'s AUC, sensitivity, specificity, *p*-value, and Youden\'s Index). Using the selected thresholds, NfL had the highest sensitivity and AUC, whereas the AD signature had the highest specificity. However, examination of the AUC confidence intervals indicated that all confidence intervals overlapped. That is, no one metric was significantly better than any of the other metrics at discriminating between the groups. Please refer to [Fig. 2](#f0010){ref-type="fig"} for boxplots of the neurodegeneration measures comparing A+ AD and A-T- CU individuals.Fig. 1A-D represent ROC curves relating sensitivity and specificity of each measure for differentiating A-T- CU from A+ AD individuals; A) CSF NfL; B) the AD signature; C) hippocampal volume; D) global atrophy.Fig. 1Table 2Diagnostic accuracy.Table 2AUC (SE)AUC 95% CIP-ValueSensitivitySpecificityYouden\'s JNfL0.943 (0.034)0.877--1.000\<0.00195.0%80.0%0.750AD signature0.928 (0.041)0.847--1.000\<0.00185.0%90.0%0.750Hippocampal volume0.885 (0.054)0.780--0.990\<0.00180.0%85.0%0.650Global atrophy0.908 (0.048)0.814--1.000\<0.00190.0%80.0%0.700[^2][^3]Fig. 2A-D represent box plots for each metric comparing A-T- CU to A+ AD individuals; A) CSF NfL; B) the AD signature; C) hippocampal volume; D) global atrophy.Fig. 2

3.3. Relationship between NfL and the MRI-based measures of N {#s0065}
-------------------------------------------------------------

Using the cut-off values derived from the ROCs to define N positivity (both for NfL and the MRI-based metrics), there was a significant relationship between NfL and all three MRI-based metrics of N (i.e., hippocampal volume, the AD signature, and global atrophy), with global atrophy having the highest concordance with NfL. Of note, the agreement among the measures of N was relatively weak. See [Table 3A](#t0015){ref-type="table"}, [Table 3B](#t0020){ref-type="table"}, [Table 3C](#t0025){ref-type="table"} for information regarding Cohen\'s Kappa, positive percent agreement, negative percent agreement, and overall percent agreement for the measures of N.Table 3AConcordance between the MRI estimates and NfL.Table 3ANfL\
N+NfL\
N-Positive % agreementNegative % agreementOverall % agreementKappa\
(p-value)AD signatureN+223232.35%85.25%72.63%0.189 (*p* = .001)N-46185Hippocampal volumeN+243335.29%84.79%72.98%0.213 (p \< .001)N-44184Global atrophyN+301444.12%93.55%81.75%0.429 (p \< .001)N-38203[^4]Table 3BConcordance between AD signature and both hippocampal volume and global atrophy.Table 3BAD signature N+AD signature N-Positive % agreementNegative % agreementOverall % agreementKappa\
(p-value)Hippocampal volumeN+223540.74%84.85%76.49%0.251 (p \< .001)N-32196Global atrophyN+212338.89%90.04%80.35%0.311 (p \< .001)N-33208[^5]Table 3CConcordance between global atrophy and hippocampal volume.Table 3CGlobal atrophy N+Global atrophy N-Positive % agreementNegative % agreementOverall % agreementKappa\
(p-value)Hippocampal volumeN+233452.27%85.89%80.70%0.341 (p \< .001)N-21207

3.4. Correlations {#s0070}
-----------------

Using the full sample, the AD signature, hippocampal volume, and global atrophy were all significantly associated with CSF levels of Aβ~42~, total tau, ptau~181~, and NfL (ps \< 0.05). These associations were similar, but attenuated, in the concordance sample. Of note, there was a strong association between CSF total tau and ptau~181~ in both samples. See [Table 4A](#t0030){ref-type="table"}, [Table 4B](#t0035){ref-type="table"}, [Table 4C](#t0040){ref-type="table"}, [Table 4D](#t0045){ref-type="table"} for the intercorrelations among the N metrics and CSF biomarkers.Table 4AAge-adjusted partial correlations in the full sample (n = 325).Table 4AAD signatureHC volumeGlobal atrophyLN AB~42~Total TauPtau~181~AD signatureHC volume0.252[⁎⁎](#tf0005){ref-type="table-fn"}Global atrophy−0.431[⁎⁎](#tf0005){ref-type="table-fn"}−0.433[⁎⁎](#tf0005){ref-type="table-fn"}LN AB~42~0.358[⁎⁎](#tf0005){ref-type="table-fn"}0.317[⁎⁎](#tf0005){ref-type="table-fn"}−0.329[⁎⁎](#tf0005){ref-type="table-fn"}Total Tau−0.347[⁎⁎](#tf0005){ref-type="table-fn"}−0.215[⁎⁎](#tf0005){ref-type="table-fn"}0.251[⁎⁎](#tf0005){ref-type="table-fn"}−0.356[⁎⁎](#tf0005){ref-type="table-fn"}Ptau~181~−0.231[⁎⁎](#tf0005){ref-type="table-fn"}−0.130[+](#tf0015){ref-type="table-fn"}0.110[+](#tf0015){ref-type="table-fn"}−0.229[⁎⁎](#tf0005){ref-type="table-fn"}0.878[⁎⁎](#tf0005){ref-type="table-fn"}NfL−0.185[⁎](#tf0010){ref-type="table-fn"}−0.148[⁎](#tf0010){ref-type="table-fn"}0.263[⁎⁎](#tf0005){ref-type="table-fn"}−0.134[+](#tf0015){ref-type="table-fn"}0.455[⁎⁎](#tf0005){ref-type="table-fn"}0.336[⁎⁎](#tf0005){ref-type="table-fn"}[^6][^7][^8][^9]Table 4BAge-adjusted partial correlations in the concordance sample (n = 285).Table 4BAD signatureHC volumeGlobal atrophyLN AB~42~Total TauPtau~181~AD signatureHC volume0.110Global atrophy−0.272[⁎⁎](#tf0020){ref-type="table-fn"}−0.325[⁎⁎](#tf0020){ref-type="table-fn"}LN AB~42~0.247[⁎⁎](#tf0020){ref-type="table-fn"}0.219[⁎⁎](#tf0020){ref-type="table-fn"}−0.162[⁎](#tf0025){ref-type="table-fn"}Total Tau−0.208[⁎⁎](#tf0020){ref-type="table-fn"}−0.0890.033−0.238[⁎⁎](#tf0020){ref-type="table-fn"}Ptau~181~−0.120[+](#tf0030){ref-type="table-fn"}−0.031−0.066−0.1060.878[⁎⁎](#tf0020){ref-type="table-fn"}NfL−0.116[+](#tf0030){ref-type="table-fn"}−0.0680.173[⁎](#tf0025){ref-type="table-fn"}−0.0450.407[⁎⁎](#tf0020){ref-type="table-fn"}0.291[⁎⁎](#tf0020){ref-type="table-fn"}[^10][^11][^12][^13]Table 4CSpearman rank correlations in the full sample (n = 325).Table 4CAD signatureHC volumeGlobal atrophyLN AB~42~Total TauPtau~181~AD signatureHC volume0.255[⁎⁎](#tf0035){ref-type="table-fn"}Global atrophy−0.380[⁎⁎](#tf0035){ref-type="table-fn"}−0.504[⁎⁎](#tf0035){ref-type="table-fn"}LN AB~42~0.323[⁎⁎](#tf0035){ref-type="table-fn"}0.330[⁎⁎](#tf0035){ref-type="table-fn"}−0.301[⁎⁎](#tf0035){ref-type="table-fn"}Total Tau−0.253[⁎⁎](#tf0035){ref-type="table-fn"}−0.258[⁎⁎](#tf0035){ref-type="table-fn"}0.338[⁎⁎](#tf0035){ref-type="table-fn"}−0.106Ptau~181~−0.189[⁎](#tf0040){ref-type="table-fn"}−0.216[⁎⁎](#tf0035){ref-type="table-fn"}0.270[⁎⁎](#tf0035){ref-type="table-fn"}−0.0790.916[⁎⁎](#tf0035){ref-type="table-fn"}NfL−0.303[⁎⁎](#tf0035){ref-type="table-fn"}−0.348[⁎⁎](#tf0035){ref-type="table-fn"}0.568[⁎⁎](#tf0035){ref-type="table-fn"}−0.156[⁎](#tf0040){ref-type="table-fn"}0.653[⁎⁎](#tf0035){ref-type="table-fn"}0.573[⁎⁎](#tf0035){ref-type="table-fn"}[^14][^15][^16]Table 4DSpearman rank correlations in the concordance sample (n = 285).Table 4DAD signatureHC volumeGlobal atrophyLN AB~42~Total TauPtau~181~AD signatureHC volume0.159[⁎](#tf0055){ref-type="table-fn"}Global atrophy−0.296[⁎⁎](#tf0050){ref-type="table-fn"}−0.444[⁎⁎](#tf0050){ref-type="table-fn"}LN AB~42~0.240[⁎⁎](#tf0050){ref-type="table-fn"}0.257[⁎⁎](#tf0050){ref-type="table-fn"}−0.211[⁎⁎](#tf0050){ref-type="table-fn"}Total Tau−0.150[+](#tf0060){ref-type="table-fn"}−0.167[⁎](#tf0055){ref-type="table-fn"}0.236[⁎⁎](#tf0050){ref-type="table-fn"}0.030Ptau~181~−0.090−0.118[+](#tf0060){ref-type="table-fn"}0.173[⁎](#tf0055){ref-type="table-fn"}0.0600.920[⁎⁎](#tf0050){ref-type="table-fn"}NfL−0.218[⁎⁎](#tf0050){ref-type="table-fn"}−0.279[⁎⁎](#tf0050){ref-type="table-fn"}0.508[⁎⁎](#tf0050){ref-type="table-fn"}−0.0440.618[⁎⁎](#tf0050){ref-type="table-fn"}0.532[⁎⁎](#tf0050){ref-type="table-fn"}[^17][^18][^19][^20]

3.5. Staging across the AD continuum {#s0075}
------------------------------------

Kruskal-Wallis tests demonstrated that there was a statistically significant association between the four measures of N (i.e., CSF NfL, AD signature, hippocampal volume, global atrophy) and AD continuum group (ps \< 0.001). Findings from Mann-Whitney *U* tests suggest that the four measures of N performed similarly in terms of differentiating A-T- CU individuals from both A+ MCI and A+ AD individuals (ps \< 0.001), with relatively large effect sizes noted (Cliff\'s deltas ≥0.741).

When comparing A-T- CU to A+T- CU individuals, only hippocampal volume was significantly different between these two groups (*p* = .016, Cliff\'s delta = 0.298), although there was a non-significant trend for both the AD signature (*p* = .051, Cliff\'s delta = 0.242) and global atrophy (*p* = .088, Cliff\'s delta = 0.211). Finally, when comparing A-T- CU to A + T+ CU individuals, CSF NfL (*p* \< .001, Cliff\'s delta = 0.731) and global atrophy (*p* = .006, Cliff\'s delta = 0.410) were significantly different between the two groups, with a non-significant trend for the AD signature (*p* = .058, Cliff\'s delta = 0.284). It is important to note that examination of the confidence intervals for Cliff\'s delta suggest that no one metric was significantly better than any of the other metrics at discriminating between the groups, with the exception that CSF NfL had a significantly larger effect size than the hippocampus when discriminating between A-T- CU and A + T+ CU individuals. See [Table 5](#t0050){ref-type="table"} for information regarding Mann-Whitney U *p*-values, as well as Cliff\'s deltas and associated confidence intervals. See [Fig. 3](#f0015){ref-type="fig"} for boxplots of the N measures for each of the five groups (i.e., A-T- CU, A+T- CU, A + T+ CU, A+ MCI, A+ AD).Table 5Comparing measures of neurodegeneration across the AD continuum.Table 5StatisticCU A-T- vs. CU A+T-CU A-T- vs. CU A + T+CU A-T- vs. MCI A+CU A-T- vs. AD A+NfLMann-Whitney U p-value0.364\<0.001\<0.001\<0.001Cliff\'s Delta0.1120.7310.8410.866Confidence interval for Cliff\'s Delta−0.152--0.3620.514--0.8600.639--0.9350.712--0.940AD signatureMann-Whitney U p-value0.0510.058\<0.001\<0.001Cliff\'s Delta0.2420.2840.7410.859Confidence interval for Cliff\'s Delta0.008--0.4510.012--0.5160.469--0.8850.727--0.930Hippocampal volumeMann-Whitney U p-value0.0160.156\<0.001\<0.001Cliff\'s delta0.2980.2120.8660.810Confidence interval for Cliff\'s Delta0.084--0.485−0.078--0.4690.778--0.9210.649--0.902Global atrophyMann-Whitney U p-value0.0880.006\<0.001\<0.001Cliff\'s Delta0.2110.4100.8560.915Confidence interval for Cliff\'s Delta−0.056--0.4500.051--0.6750.507--0.9640.644--0.982[^21]Fig. 3A-D represent box plots for each metric comparing the different groups (CU A-T-, CU A+T-, CU A+T+, MCI A+, AD A+); A) CSF NfL; B) the AD signature; C) hippocampal volume; D) global atrophy.Fig. 3

3.6. Post-hoc analyses: staging across the AD continuum, adjusting for age {#s0080}
--------------------------------------------------------------------------

Results adjusting for age were largely unchanged, with the exception that there was no longer a trend for global atrophy when comparing A-T- CU to A+T- CU individuals (*p* = .562, Cliff\'s delta = 0.072). Furthermore, only CSF NfL significantly differed between the A-T- CU and the A + T+ CU groups (p \< .001, Cliff\'s delta = 0.527). See [Supplemental Table 1](#ec0015){ref-type="supplementary-material"} for information regarding Mann-Whitney U p-values, as well as Cliff\'s deltas and associated confidence intervals. See [Supplemental Fig. 2](#ec0010){ref-type="supplementary-material"} for boxplots of the N measures for each of the five groups (i.e., A-T- CU, A+T- CU, A + T+ CU, A+ MCI, A+ AD), adjusting for age.

4. Discussion {#s0085}
=============

The current study sought to compare three commonly used MRI morphometric operationalizations of N: global atrophy, hippocampal volume, and an implementation of the AD signature from FreeSurfer. These three metrics were selected for study because they are commonly used in the field and prior literature has suggested all three are associated with structural changes in AD ([@bb0080]; [@bb0075]; [@bb0090]; [@bb0115]; [@bb0140]; [@bb0255]; [@bb0260]; [@bb0285]). Regarding diagnostic accuracy, hippocampal volume, global atrophy, and the thickness-based AD signature, along with CSF levels of NfL, performed similarly in terms of differentiating A+ AD from A-T- CU individuals. The highest sensitivity and AUC were reported for CSF NfL, whereas the highest specificity was noted for the AD signature; however, the overlapping confidence intervals suggest no strong inferences are warranted. The similar performance of these three metrics may be due to the fact that at the dementia stage of AD, atrophy is present throughout the brain ([@bb0250]; [@bb0275]). In summary, these findings suggest that for the purpose of identifying individuals with dementia due to AD, N could be defined using any of the three available MRI metrics or CSF NfL.

When applying the N cut-off values derived from the ROC analyses to a larger sample containing A-T- CU, A+T- CU, A + T+ CU, and A+ MCI individuals, global atrophy had a relatively higher concordance with CSF NfL than the other two MRI-based metrics of N; however, it is important to emphasize that all three metrics had weak agreement with CSF NfL and with each other (i.e., Cohen\'s Kappa values ≤0.429; [@bb0105]; [@bb0110]). Similarly, small to moderate inter-correlations were observed for these four metrics of N. These findings are consistent with prior research ([@bb0010]; [@bb0145]; [@bb0290]; [@bb0315]), suggesting that these measures appear to provide different information related to N. Despite this low level of agreement, results from Mann-Whitney *U* tests and Cliff\'s deltas, unadjusted for age, indicated similar performance in terms of differentiating the A-T- CU group from the AD continuum groups (i.e., A+T- CU, A + T+ CU, A+ MCI, and A+ AD). These findings fit with previous research indicating that different definitions of N produce similar results, including that individuals defined as N+ using a number of different approaches (e.g., hippocampal volume, thickness-based AD signature, FDG-PET) performed more poorly on tests of learning and memory than N- individuals ([@bb0145]).

The findings were largely unchanged when adjusting for age, with the exception that there was no longer a trend for global atrophy when comparing A-T- CU to A+T- CU individuals. Furthermore, only CSF NfL significantly differed between the A-T- CU and the A + T+ CU groups. The best approach to account for "normal" (i.e., non-pathologic) age-related change is yet to be determined in the literature for not only structural MRI and CSF NfL, but also for other areas of study such as cognition. Furthermore, previous investigations differ in whether and how they adjust for age when examining N (e.g., [@bb0010]; [@bb0145]; [@bb0290]; [@bb0315]). In the current study, we tried to estimate age-related changes by examining the relationship between N and age in the A-T- CU group. We then applied the parameters from this group to calculate age-adjusted values of N for individuals across the AD continuum. The findings from the current study do indicate that CSF NfL has the added benefit of similarly distinguishing A-T- CU from A + T+ CU individuals, with and without adjusting for age. Unfortunately, adjusting for age resulted in none of the MRI-based measures differing between the A-T- CU and A + T+ CU groups. Furthermore, this approach did not account for other pathologic changes (e.g., cerebrovascular disease) that may impact estimates of N in the context of aging. The field would benefit from future studies with larger groups across the AD continuum to determine the best approach for adjusting for non-pathologic aging and whether any of the three MRI-based metrics of N is preferable for defining N when accounting for age-associated changes.

Although the present results indicate that any of the three MRI-based measures may be used to define N across the AD continuum, the measure of global atrophy in the current study may be preferable to the other measures for methodological reasons. First, the global atrophy metric is less affected by the limitations of current segmentation techniques. In particular, previous research indicates reduced gray to white contrast with aging, which will affect the estimates of any metric requiring segmentation of gray from white matter structures, and may result in less accurate volumetric and thickness estimates ([@bb0100]). Because the measure of global atrophy was a ratio of CSF volume to white and gray matter volumes (summed), this metric is by design impervious to gray and white matter segmentation uncertainties that were inherent to thickness and hippocampal volumetric estimates. This benefit of the global atrophy estimate is worth emphasizing given existing literature demonstrating that white matter signal intensity declines with age ([@bb0245]) and is impacted by disease status, with AD patients evidencing lower signal intensity and gray to white matter contrast than their CU counterparts ([@bb0320]). Together, these findings would suggest that estimates that do not rely on differentiating gray from white matter may be preferable when defining N across the AD continuum.

In contrast to the hippocampal volumetric estimate, both the global atrophy metric and the AD signature had the added benefit of not needing to correct for head size as it was a ratio of CSF to white and gray matter volumes (summed). In the current study, we controlled for head size by dividing hippocampal volume by intracranial volume. A number of other approaches have been used to correct for head size variation (e.g., [@bb0050]; [@bb0205]; [@bb0240]), and currently, there is no universally agreed upon method. Considering that the method employed to account for head size can result in significant variability across studies, a metric like global atrophy, which does not require head size correction, may be preferable when defining N across the AD continuum.

Even though the thickness-based AD signature did not require head size correction, the potential uncertainties related to the accuracy and reliability of FreeSurfer may make this measure less than optimal for defining N across the AD continuum. Specifically, prior research suggests some problems with the accuracy of atlas-based FreeSurfer generated estimates in the temporal lobe (a region included in the current AD signature; [@bb0070]; [@bb0210]). Furthermore, although the AD signature was composed of estimates from a number of regions, a prior investigation indicates lower reliability for regions with smaller surface areas, such as the entorhinal cortex, which was included in the AD signature in this study ([@bb0070]). For these reasons, global atrophy may be preferable to the thickness-based AD signature derived from FreeSurfer for defining N across the AD continuum.

Despite the emphasis of the present study on MRI-derived measures of N and CSF NfL, it is important to highlight the strong association noted between total tau and ptau~181~ in the current analysis. The AT(N) framework developed by [@bb0160] classifies CSF total tau as a measure of N, whereas ptau~181~ is considered a metric of T. Despite prior investigations indicating that CSF levels of total tau and ptau~181~ may diverge in other neurodegenerative conditions, such as Creutzfeldt-Jakob disease ([@bb0270]) and certain clinical variants of frontotemporal dementia ([@bb0195]), treating CSF measures of total tau and ptau~181~ as reflecting N and T, respectively, may be less helpful in terms of staging individuals across the AD continuum given their strong association. Within the context of the current findings, a different measure of N, such as one obtained using structural MRI or CSF NfL, may be preferable to the use of total tau for defining N in individuals across the AD continuum.

The current findings should be considered within the context of several limitations. First, even though the present work suggests similar effect sizes for the four measures when defining N across the AD continuum, this study only examined CSF NfL and three out of a potentially very large number of candidate MRI metrics of atrophy that have been presented in the literature ([@bb0025]; [@bb0120]). In addition to constraining our examination of N to four measures, each of the four measures was examined independently. There is some research to suggest that a combination of N markers may be the best approach when defining N. For example, relatively recent work suggests that A+ CU individuals who are N+ based on both CSF total tau and hippocampal volume tend to be at greater risk of clinical decline when compared to A+ CU individuals who are N+ on only CSF total tau or hippocampal volume ([@bb0315]). Additionally, a recent study found that a combined MRI measure of atrophy and cerebrovascular disease was associated with PET amyloid imaging, CSF biomarkers, and neuropathology at autopsy in individuals across the AD continuum ([@bb0045]). Subsequent work should explore how independent measures compare to a combination of measures (e.g., structural MRI estimates, CSF levels of NfL, FDG-PET, and/or diffusion tensor imaging) for defining N across the AD continuum. Considering that individuals with AD frequently have cerebrovascular disease ([@bb0170]), future AD-related research could compare different N measures in conjunction with measures of cerebrovascular disease (e.g., cerebral blood flow and pulsatility) ([@bb0125]).

Limitations related to the sample in this study should also be acknowledged. Although a strength of the current study is that individuals in the A+ AD group were matched to A-T- CU individuals on age, sex, and education, the sample sizes for the groups were relatively small (i.e., *n* = 20 in each of the AD and biomarker-negative CU groups). Similar small sample sizes were observed for the other groups across the AD continuum (i.e., n = 20 A+T- CU, *n* = 16 A + T+ CU, and 16 A+ MCI). Furthermore, the participants were generally well educated with a mean education level of approximately 16 years. These constraints may limit the generalizability of the current findings. Additional research with a larger and more diverse sample is needed. In particular, considering that we constrained our examination to individuals who were along the AD continuum, as well as excluded CU individuals with significant cerebrovascular disease, subsequent research is needed to determine the optimal way to define N in individuals with other neurodegenerative conditions, including those who are A-T+. Finally, future research using the three MRI-based metrics from the current study may also examine the degree to which biomarker-positive CU individuals who are N+ go on to develop dementia due to AD.

A final limitation of the current study is that the cut-off values used to define N were determined based on their ability to differentiate A+ individuals with a clinical diagnosis of probable AD from A-T- CU individuals. These cut-off values were then used in a subsequent analysis to examine the concordance between the three MRI-based metrics and CSF NfL. In an ideal scenario, there would be some "true" cut-off value of NfL, or another marker of N, that defines the presence of neurodegeneration independent from clinical status. We would then use this cut-off value to evaluate our MRI-based metrics. Unfortunately, no agreed upon measure currently exists for NfL or any other measure of neurodegeneration (separate from clinical status) for defining N ([@bb0150], [@bb0160]). Future work should reexamine this question once an independent reference standard becomes available.

Within the context of these limitations, the current study suggests that the global atrophy metric may represent a convenient MRI-based measure for defining N across the AD continuum. Specifically, global atrophy was similar to hippocampal volume and the AD signature for differentiating A+ AD dementia individuals from A-T- CU individuals, as well as for differentiating A-T- CU individuals from A+T- CU, A + T+ CU, and A+ MCI. The fact that the global atrophy metric required less human and computational resources and is not affected by methodological issues that may affect complex approaches (e.g., gray from white matter demarcation and atlas based parcellation) also favors the use of global atrophy as a measure of neurodegeneration. The choice of an MRI neurodegeneration metric employed in any particular study will depend on the specific research question and should consider the precision, reliability, and complexity of the approach given the quality of the input image data. Taken together, these findings provide justification for considering global atrophy as a general and robust MRI-based metric for evaluating N across the AD continuum.

The following are the supplementary data related to this article.Supplementary Fig. 1Flow diagram depicting eligibility for the current study. Arrows pointing downward indicate number of participants excluded at each decision point. Arrows pointing upward indicate number of participants included at each decision point.Supplementary Fig. 1Supplementary Fig. 2Adjusting for age (see text for more details), A-D represent box plots for each metric comparing the different groups (CU A-T-, CU A+T-, CU A+T+, MCI A+, AD A+); A) CSF NfL; B) the AD signature; C) hippocampal volume; D) global atrophy.Supplementary Fig. 2Supplementary Table 1Supplementary Table 1
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Results were unchanged when only A + T+ AD individuals and their matched A-T- CU counterparts (*n* = 36) were included in the analyses.

[^1]: Notes: ROC = receiver operating characteristic; CU = cognitively unimpaired; AD = Alzheimer\'s disease; MCI = mild cognitive impairment; LN = natural-log; CSF = cerebrospinal fluid; NfL = neurofilament light chain protein; \^there were significantly more females in the CU group than the MCI group; \*the CU group was significantly younger than the AD and MCI groups, but the MCI group was significantly older than the AD group; +one CU A-T- participant in the concordance sample was missing education.

[^2]: Notes: AUC = area under the curve; SE = standard error; NfL = neurofilament light chain protein;

[^3]: AD = Alzheimer\'s disease.

[^4]: Notes: NfL = neurofilament light chain protein; AD = Alzheimer\'s disease.

[^5]: Note: AD = Alzheimer\'s disease.

[^6]: Notes: AD = Alzheimer\'s disease; HC = hippocampal; LN = natural log; NfL = neurofilament light chain protein.

[^7]: *p* \< .001.

[^8]: *p* \< .01.

[^9]: *p* \< .05.

[^10]: Notes: AD = Alzheimer\'s disease; HC = hippocampal; LN = natural log; NfL = neurofilament light chain protein.

[^11]: p \< .001.

[^12]: p \< .01.

[^13]: p \< .05.

[^14]: Notes: AD = Alzheimer\'s disease; HC = hippocampal; LN = natural log; NfL = neurofilament light chain protein.

[^15]: p \< .001.

[^16]: p \< .01.

[^17]: Notes: AD = Alzheimer\'s disease; HC = hippocampal; LN = natural log; NfL = neurofilament light chain protein.

[^18]: p \< .001.

[^19]: p \< .01.

[^20]: p \< .05.

[^21]: Notes: NfL = neurofilament light chain protein; CU = cognitively unimpaired; MCI = mild cognitive impairment; AD = Alzheimer\'s disease.
